Form 4: Citius Oncology Insider Reports Significant Equity Awards

Myron Z. Holubiak, Director and Secretary of Citius Oncology, Inc., reported substantial equity awards, including restricted stock and stock options.

Summary

• Myron Z. Holubiak, a Director and Secretary of Citius Oncology, Inc. (CTOR), reported the acquisition of 850,000 shares of common stock as restricted stock awards.
• These restricted stock awards were granted on September 19, 2025, at a price of $0, and are scheduled to vest in three substantially equal installments on the first, second, and third anniversaries of the grant date, contingent on continuous service to the Company or a Related Entity.
• An additional 100,000 shares of restricted stock were granted on September 19, 2025, to Mr. Holubiak's daughter, with the same vesting schedule, for which he disclaims beneficial ownership.
• Mr. Holubiak also holds 300,000 stock options with an exercise price of $1.07, granted on December 12, 2024, and expiring on December 12, 2034. These options will vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the grant date, subject to continuous service.
• An additional 50,000 stock options with the same terms (exercise price $1.07, granted December 12, 2024, expiring December 12, 2034) are held by his daughter, for which he disclaims beneficial ownership.
• Furthermore, Mr. Holubiak holds 1,500,000 stock options with an exercise price of $2.15, granted on July 5, 2023, and expiring on July 5, 2033. These options vest over three years, with 1/36th vesting monthly for the first year, and 1/3 vesting on each of the second and third anniversaries of the July 5, 2023, grant date, subject to continuous service.

Sentiment

Score: 7

Explanation: The filing indicates significant equity awards to a key insider, aligning management interests with long-term shareholder value, which is generally a positive signal for investor confidence and company stability.

Positives

• The significant equity awards to a key director and officer, Myron Z. Holubiak, demonstrate strong alignment of management's long-term interests with shareholder value.
• The multi-year vesting schedules for both restricted stock and stock options incentivize sustained performance and long-term commitment from the reporting person.

Risks

• Vesting of restricted stock and stock options is contingent upon the Reporting Person's continuous service to Citius Oncology, Inc. or a Related Entity, meaning the awards could be forfeited if service is terminated prematurely.

Future Outlook

The equity awards, particularly with multi-year vesting schedules, indicate a long-term incentive structure designed to align the reporting person's interests with the future performance and growth of Citius Oncology, Inc.

Industry Context

This Form 4 filing is a standard disclosure of insider equity transactions and does not provide information directly related to broader industry trends or competitors. However, equity compensation is a common practice across industries to attract, retain, and incentivize key personnel.

Related Party Transactions

• Restricted stock awards of 100,000 shares and stock options for 50,000 shares were granted to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.

Stakeholder Impact

• Shareholders: The significant equity grants to a key executive align management's financial interests with the long-term performance of the company, potentially benefiting shareholders through increased motivation for value creation.
• Employees: The compensation structure for a senior executive may set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• The restricted stock awards will vest in three substantially equal installments on the first, second, and third anniversaries of September 19, 2025.
• The stock options granted on December 12, 2024, will vest 1/3 on each of the one-year, two-year, and three-year anniversaries of the grant date.
• The stock options granted on July 5, 2023, will continue to vest monthly for the first year (1/36th) and then 1/3 on the second and third anniversaries of the grant date.

Key Dates

Recommendation

The significant equity awards to a key director and officer, Myron Z. Holubiak, demonstrate a strong alignment of management's long-term interests with shareholder value. While this filing does not provide financial performance data, the substantial grants of restricted stock and stock options, with multi-year vesting schedules, suggest confidence in the company's future and incentivize sustained performance. This insider activity supports a 'hold' recommendation, as it indicates management is committed and incentivized for long-term growth, without providing new information to warrant a 'buy' or 'sell' based solely on this disclosure.

Keywords

Citius Oncology, CTOR, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock, Stock Options, Equity Awards, Myron Z. Holubiak